Figure 1.
We dedicate this supplement to the memory of our late coauthor, colleague, and friend, Mark A. Wainberg, PhD. Dr Wainberg was director of the McGill University AIDS Centre at the Montreal Jewish General Hospital and professor of medicine and of microbiology at McGill University. He was a leader in human immunodeficiency virus (HIV) research who was the first to describe the anti-HIV activity of lamivudine. As a pioneer in the field of HIV drug resistance, his many significant contributions illuminated the mechanisms of antiretroviral drug resistance and the challenges of antiretroviral resistance in low- and middle-income countries. Mark was also a statesman and a humanitarian. As president of the International AIDS Society (1998–2000), he was instrumental in bringing the 2000 International AIDS Conference to Durban, South Africa, the first such conference to be held in Africa. He advocated tirelessly for the rights of all persons living with HIV infection and for universal access to antiretroviral therapy, bravely standing up to politicians and AIDS denialists who impeded the provision of life-saving antiretroviral therapy to those in need. For these notable accomplishments, Mark was made Officer of the Order of Canada, Officer of the National Order of Québec, Fellow of the Royal Society of Canada, and Knight of the National Order of the Legion of Honor in France. His absence is deeply felt, but his legacy inspires all who follow in his footsteps.
Notes
Supplement sponsorship. This article is part of a supplement sponsored by the National Institute of Allergy and Infectious Disease, NIH, and the Centers for Disease Control and Prevention.
Potential conflicts of interest. Author confirmed no potential conflicts. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.